Approximately 1 in 20 adults with outpatient respiratory syncytial virus (RSV) infections were readmitted to the hospital ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...

The findings of a study into the effect of COVID-19 vaccines on children are being misrepresented in posts shared on social ...

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...

As a company focused on delivering a re-purposed erectile dysfunction drug via a nasal spray, LTR Pharma is a simple story to ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...

Is Pfizer stock a sell after shares skidded on the news Trump selected Kennedy to take over HHS? Is PFE stock now a sell? Billionaire Israel Englander Is Selling Nvidia and Palantir and Buying a ...

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

Pfizer Canada ULC is pleased to announce the appointment of An Van Gerven as President. Previously, An was Country Manager, ...